Rheos Medicines is a biopharmaceutical company developing novel medicines that modulate metabolic pathways in immune cells to treat disease. Our approach targets the underlying cellular metabolism of immune cells to redirect the fate and function of specific cell types to treat immune-mediated disease. By simultaneously identifying new drug targets and characterizing biomarkers of disease we are bringing precision to the treatment of immune-mediated diseases. We have brought together leading scientists whose discoveries opened the field of immunometabolism, clinicians with a deep understanding of immune-mediated diseases, and an experienced biotech leadership team.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/22/18 | $60,000,000 | Series A |
Third Rock Ventures | undisclosed |
